-
Physician-investigators to discuss definition, implications of remission in type 2 diabetes
Since the publication of the Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in 2021, the applicability of remission as a realistic treatment goal has evolved. A panel including Hertzel C. Gerstein, MD, MSc, FRCPC, will discuss the concept of remission in diabetes and its potential in research and patient care.
-
Panel to examine challenges of diabetes care and prevention in immigrant populations
Experts including Aimee Afable, PhD, MPH, will discuss the growing risk of diabetes in populations that immigrate to the U.S. and what may be leading to those risk factors. Discussions will include the challenges of adapting programs and approaches in treating and mitigating diabetes to meet the needs of culturally distinct communities.
-
Experts to explore drugs’ potential to delay type 1 diabetes
Last fall, the U.S. Food and Drug Administration approved teplizumab as the first disease-modifying therapy in type 1 diabetes. Experts including Stephen E. Gitelman, MD, will present insights from studies of teplizumab and other agents, including abatacept and hydroxychloroquine, that have provided road maps to help delay the onset of disease.
-
Session will highlight diabetic retinopathy risk factors
People with diabetes are at risk for retinopathy. Ward Fickweiler, MD, will discuss research exploring the relationship between the presence of age-related macular degeneration and diabetic retinopathy severity in people with type 1 diabetes. Other panelists will discuss glucose management, prior cerebrovascular disease, and autonomous artificial intelligence diabetic eye exams.